Polycystic Metabolic Ovarian Syndrome (PMOS) is the new clinical name for the condition long known as Polycystic Ovary Syndrome (PCOS). The change reflects a deeper scientific understanding that insulin resistance and metabolic dysfunction sit at the center of the syndrome, not the ovaries alone. This article sets out to explain the differences between PCOS and PMOS, the role of insulin resistance, and how myo-inositol supplementation fits into modern management of the condition.
From PCOS to PMOS: what changed and why
The renaming of PCOS to PMOS followed a decade of work led by researchers at Monash University in Australia, with input from more than 50 organizations and over 22,000 patients and clinicians. The shift was published in The Lancet and reflects how the medical understanding of the condition has evolved.
The old name pointed almost entirely to the ovaries. The new name acknowledges three connected pillars:
- The endocrine system, where rapid hormonal pulses from the brain drive an imbalance between luteinizing hormone and follicle-stimulating hormone.
- The metabolic system, where insulin resistance amplifies androgen production and drives long-term cardiovascular and diabetes risk.
- The ovaries, where arrested follicles, irregular cycles, and fertility challenges show up as the visible result of the upstream problems.
Researchers and doctors now describe PMOS as a whole-body condition. It affects energy, weight, mood, heart health, and reproduction. The name change signals that it is no longer treated as a gynecological problem alone.
How PCOS and PMOS differ in focus
Many women read about the renaming and wonder if they have a different condition. They do not. The diagnosis, the affected population, and the underlying biology are the same. What has changed is the lens through which physicians are encouraged to view and treat it.
The key differences in focus include:
- Diagnostic emphasis. PCOS focused on ovarian cysts seen on ultrasound. PMOS recognizes that many women with the condition never develop visible cysts, while many who do have cysts have no symptoms.
- Clinical attention. PCOS care often centered on cycle regulation and fertility. PMOS care expects a metabolic workup as part of every diagnosis – fasting insulin, glucose, lipids, and blood pressure.
- Treatment scope. PCOS treatment historically meant birth control pills and lifestyle advice. PMOS treatment now includes insulin sensitizers, GLP-1 receptor agonists, targeted supplements, and cardiovascular monitoring.
- Specialist involvement. PCOS was largely managed by gynecologists. PMOS calls for primary care, endocrinology, cardiology, and mental health to share the patient.
According to the 2023 International Evidence-Based Guideline, a diagnosis can now be made when a patient shows irregular cycles together with hyperandrogenism. An ultrasound is no longer required in adult women if both features are present.
Why insulin resistance sits at the center
Insulin resistance is the feature that the old name made invisible. Research now shows that insulin resistance is present in approximately 70 to 85 percent of people with PMOS – including roughly 75 percent of lean women with the condition. This is the single most important reason for the renaming.
The mechanism is a self-reinforcing loop:
- The body becomes less responsive to insulin, so the pancreas produces more.
- Excess insulin stimulates the ovaries to produce more testosterone.
- High insulin also lowers sex hormone-binding globulin, which means more free testosterone circulates in the body.
- Higher androgens feed back to the brain, speeding up the hormonal signals that drive ovarian dysfunction.
This loop explains many of the symptoms women with PMOS experience:
- irregular periods
- weight that resists diet and exercise
- acne along the jawline and back
- scalp hair thinning
- unwanted hair growth.
It also explains the long-term risks: type 2 diabetes onset roughly ten years earlier than the general population, elevated cardiovascular risk during the reproductive years, and a higher prevalence of non-alcoholic fatty liver disease.
Common symptoms and what they signal
Symptoms of PMOS overlap with the older PCOS definition but are now interpreted through a metabolic filter:
- Irregular, infrequent, or absent menstrual cycles caused by disrupted ovulation.
- Hyperandrogenism, visible as adult acne, hirsutism on the face and body, and androgenic hair loss on the scalp.
- Difficulty losing weight, especially around the abdomen, even with consistent effort.
- Elevated fasting insulin, abnormal lipid panels, and signs of acanthosis nigricans on the neck or underarms.
- Anxiety, low mood, and sleep disturbance, now understood as part of the inflammatory and hormonal picture.
- Fertility challenges and a higher risk of gestational diabetes during pregnancy.
Each of these symptoms is a clinical sign of the broader cascade, not an isolated problem to be managed on its own.
The role of myo-inositol in PMOS management
Inositol is a naturally occurring compound that helps cells respond to insulin and follicle-stimulating hormone. Two forms matter clinically: myo-inositol, which supports follicle development and ovarian signaling, and D-chiro-inositol, which assists insulin-related conversion. In a healthy ovary, myo-inositol is the dominant form. In insulin-resistant states, this balance is disrupted at the follicular level, which impairs egg quality and contributes to androgen excess.
Supplementation aims to restore the natural ratio inside the follicle. Clinical reviews have found that myo-inositol supplementation can:
- Improve insulin sensitivity over weeks of consistent use.
- Support ovulation and improve menstrual regularity.
- Reduce circulating androgen levels, which can ease acne and hirsutism over time.
- Improve egg quality in women planning to conceive.
Inositol Plus (myo-inositol) combines myo-inositol with supporting nutrients formulated to address the metabolic side of PMOS. Inositol Plus is one option women can discuss with their physician as part of a wider PMOS management plan that may also include lifestyle changes and prescription therapy. Inositol Plus is available through IsraelPharm, a licensed international pharmacy that supplies medications and supplements with physician oversight unaffected.
Diagnosis and broader treatment options
Diagnosis under the updated guideline is more straightforward than it used to be. A physician can confirm PMOS based on clinical features alone in many adult women, supported by laboratory tests that look beyond the ovaries. A complete workup commonly includes:
- Fasting insulin and fasting glucose to calculate HOMA-IR, a measure of insulin resistance.
- A full lipid panel with particular attention to triglycerides and HDL cholesterol.
- Liver function tests and, where indicated, an abdominal ultrasound to assess for fatty liver.
- Total and free testosterone, DHEA-S, and SHBG to characterize androgen activity.
- Anti-Müllerian hormone (AMH), now recognized as both a fertility marker and a marker of disease activity.
Treatment is built around the metabolic core. Lifestyle changes, a diet lower in processed carbohydrates, regular physical activity, adequate sleep, and stress management, remain foundational. Inositol supplementation, Metformin, and in selected cases GLP-1 receptor agonists address insulin resistance directly. Fermented foods and prebiotic fiber are supported by recent microbiome research as part of the wider plan.
Treatment for PMOS is long-term and should always be guided by a healthcare provider who can monitor progress and adjust the plan.
How to access PMOS treatment options through IsraelPharm
For women managing PMOS, ongoing access to the right supplements and prescription medications matters. IsraelPharm is a licensed international pharmacy that supplies Inositol Plus and other prescribed therapies women may use as part of a PMOS treatment plan agreed with their physician.
Three advantages are relevant for women researching their options:
- Legitimacy. IsraelPharm operates under Health Ministry oversight, and all prescriptions are dispensed by a licensed pharmacist. Physician oversight of treatment is not affected by sourcing through an international pharmacy.
- Access. IsraelPharm stocks the exact branded products prescribed, including formulations that can be difficult to source consistently through US channels.
- Continuity. For conditions that respond best to consistent, long-term treatment, reliable supply matters. Orders are delivered to the home, and patient records support repeat reminders so treatment stays on schedule.
A valid prescription from a licensed physician is required for all prescription medications, but Inositol Plus is available as a supplement . We encourage you to discuss use of any new supplements and medications with a healthcare provider before starting. Women researching PMOS, insulin resistance, or myo-inositol can find more product information and condition resources on the IsraelPharm website.
Further reading
- Polycystic ovary syndrome fact sheet: World Health Organization
- About polycystic ovary syndrome: National Institute of Child Health and Human Development
- 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome: Journal of Clinical Endocrinology & Metabolism
- Polycystic ovary syndrome (PCOS): Cleveland Clinic
- Polycystic ovary syndrome (PCOS): Endocrine Society
- Insulin resistance and PCOS: IsraelPharm blog
- Inisotol Plus – a new alternative to metformin for women with PCOS: IsraelPharm blog
Frequently asked questions
What is the difference between PCOS and PMOS?
PCOS and PMOS describe the same condition, but the focus has changed.
- PCOS framed it as an ovarian and reproductive problem.
- PMOS recognizes insulin resistance and metabolic dysfunction as central drivers.
- The new name encourages broader screening, including lipids, fasting insulin, and cardiovascular risk.
- It also widens the care team to include endocrinology and primary care.
The renaming does not change a prior diagnosis – it changes how the condition is understood and managed.
How does insulin resistance drive PMOS symptoms?
Insulin resistance creates a self-reinforcing loop that fuels most PMOS symptoms.
- The pancreas produces extra insulin to overcome resistance.
- High insulin stimulates the ovaries to produce excess testosterone.
- Insulin lowers SHBG, raising the level of free testosterone.
- The androgen excess drives acne, hirsutism, hair loss, and cycle disruption.
Addressing insulin resistance through diet, exercise, and insulin-sensitizing therapies often improves multiple PMOS symptoms at once.
Can myo-inositol help with PMOS?
Myo-inositol can support women with PMOS by improving how cells respond to insulin and hormonal signals.
- It supports follicle development and ovarian signaling.
- It can improve ovulation rates and menstrual regularity.
- It may reduce circulating androgen levels over weeks of use.
- It is generally well tolerated compared with some prescription options.
Women should speak to a physician before adding myo-inositol to a treatment plan, especially when combining it with prescription medications.
Is Inositol Plus a prescription medication?
Inositol Plus is a supplement, not a prescription medication.
- It contains myo-inositol and supporting nutrients formulated for metabolic support.
- It can be used alongside prescription PMOS therapies under physician guidance.
- It is intended for long-term, consistent daily use to support insulin sensitivity.
Because individual response varies, women should review Inositol Plus with a healthcare provider who knows their full medical history and current treatment plan.
Where can I access Inositol Plus and other PMOS medications?
Inositol Plus is available through IsraelPharm, a licensed international pharmacy.
- IsraelPharm dispenses both supplements and prescription medications used in PMOS care.
- A valid prescription from a licensed physician is required for all prescription products.
- Orders are delivered to the home with tracking from door to door.
- Repeat reminders help patients maintain continuity of treatment.
Women managing PMOS long-term appreciate the reliable supply and savings that home-delivery from IsraelPharm provides.
Glossary
- Androgens: A group of hormones, including testosterone, that influence reproductive and skin-related traits and are often elevated in PMOS.
- Anti-Müllerian hormone (AMH): A hormone produced by small ovarian follicles that is typically elevated in PMOS and reflects ovarian activity.
- Folliculogenesis: The biological process by which ovarian follicles grow, mature, and release an egg during a normal menstrual cycle.
- Follicle-stimulating hormone (FSH): A pituitary hormone that supports follicle growth and is often relatively low in women with PMOS.
- Hyperandrogenism: A clinical state of elevated androgen activity, causing symptoms such as acne, hirsutism, and androgenic scalp hair loss.
- Hyperinsulinemia: A condition in which the pancreas releases more insulin than normal, typically in response to underlying insulin resistance in tissues.
- Insulin resistance: A state in which cells respond poorly to insulin, prompting the pancreas to produce higher levels to maintain blood glucose control.
- Luteinizing hormone (LH): A pituitary hormone that triggers ovulation and stimulates androgen production; it is often elevated in PMOS.
- Myo-inositol: A naturally occurring compound that supports insulin signaling and follicle development and is widely used in PMOS supplementation.
- Oligoanovulation: Infrequent or absent ovulation, which causes the irregular or missed menstrual cycles often seen in PMOS.
- Sex hormone-binding globulin (SHBG): A liver-produced protein that binds androgens; low SHBG raises free testosterone and worsens PMOS symptoms.
